Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 trial of VT-1953

Next Previous
Trial Profile

Phase 3 trial of VT-1953

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VB 1953 (Primary)
  • Indications Wounds
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 11 Feb 2026 According to a Vyome Holdings media release, Company has required capital on hand to reach critical interim results from the Phase 3 efficacy study, expected in mid-2027.
  • 11 Feb 2026 According to a Vyome Holdings media release, all contract research organizations (CRO) necessary to complete the Phase 3 are currently engaged with clear cost expectations.
  • 11 Feb 2026 According to a Vyome Holdings media release, FDA interaction on the Phase 3 protocol is planned in Q2 of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top